The transcription factor ATF6 is held as a membrane precursor in the endoplasmic reticulum (ER), and is transported and proteolytically processed in the Golgi apparatus under conditions of unfolded protein response stress. We show that during stress, ATF6 forms an interaction with COPII, the protein complex required for vesicular traffic of cargo proteins from the ER. Using an in vitro budding reaction that recapitulates the ER-stress induced transport of ATF6, we show that no cytoplasmic proteins other than COPII are necessary for transport. ATF6 is retained in the ER by association with the chaperone BiP (GRP78). In the in vitro reaction, the ATF6-BiP complex disassembles when membranes are treated with reducing agent and ATP. A hybrid protein with the ATF6 cytoplasmic domain replaced by a constitutive sorting signal (Sec22b SNARE) retains stress-responsive transport in vivo and in vitro. These results suggest that unfolded proteins or an ER luminal ؊SH reactive bond controls BiP-ATF6 stability and access of ATF6 to the COPII budding machinery.
regulated transport ͉ unfolded protein response ͉ BiP ͉ prebudding complex E ndoplasmic reticulum (ER) homeostasis can be perturbed by up-regulation of secretory proteins or by disruption of protein processing, a condition termed ER stress (1) . ER stress causes increased protein misfolding and leads to activation of the unfolded protein response (UPR), an evolutionarily conserved pathway to alleviate ER stress (2) . The UPR leads to a slowdown in protein synthesis, an upregulation of ER chaperones, and an upregulation of ER-associated protein degradation.
The three effector proteins for the UPR are IRE1, PERK, and ATF6. During the UPR, IRE and PERK remain in the ER and act via cytoplasmic effectors, whereas ATF6 is transported to the Golgi complex. In the Golgi, ATF6 is cleaved by Site-1 and Site-2 proteases (3). These cleavages release the N-terminal cytoplasmic domain, which contains a bZIP motif that binds DNA at ER stress response elements that control expression of the ER chaperones BiP (GRP78) and GRP94 (4) .
Transport of ATF6 and other cargo proteins likely involves the COPII coat, a complex of five cytoplasmic proteins that selects cargo at the ER membrane and pinches off membranes to form vesicles. The five proteins are the GTPase Sar1, which is recruited to the ER membrane and initiates coat formation by GDP to GTP exchange; the heterodimeric complex Sec23/Sec24, which binds to Sar1⅐GTP; and a second dimeric complex, Sec13/Sec31, which binds to Sec23/24 and provides the curvature necessary for vesicle fission (5) . Cargo is selected by interactions between domains on the Sec24 subunit and cytoplasmic motifs on cargo proteins (6) . Inhibition of COPII by overexpression of dominant negative Sar1 has been shown to block transport of ATF6 (7) .
A central question in ATF6 function is how luminal stress is converted into recognition by the cytoplasmic COPII complex. The luminal chaperone BiP binds ATF6 stably in unstressed cells and dissociates specifically during stress (8) . The triggers for this release are unclear. Structural studies of IRE1, which is also controlled by BiP, have posited direct recognition of misfolded proteins that induces a conformation change to the active state (9, 10) . Whether ATF6 is triggered by a similar mechanism of misfolded protein binding is unclear.
Evidence supports a model in which accessory proteins are necessary for ATF6 transport. When the luminal domain of ATF6 was fused to the cytoplasmic domain of the ER-localized protein LZIP, the chimera still trafficked to the Golgi during ER stress (11) , demonstrating that the ATF6 cytoplasmic domain is not required for transport. A sorting signal may be provided by a cargo receptor that engages ATF6 in the ER lumen and COPII in the cytoplasm, an interaction occurring specifically during stress.
We have established in vitro reactions that recapitulate ATF6 dissociation from BiP and engagement with COPII during stress. These data show that during stress ATF6 undergoes alterations that deliver it to COPII vesicles for transport.
Results

ATF6 Transport Is Recapitulated in Vitro in a Cell Line Stably Express-
ing FLAG-ATF6. To assess ATF6 transport, we generated a stable CHO cell line, CHO-ATF6, expressing full-length ATF6 with three copies of the FLAG epitope at the N terminus (12) . CHO-ATF6 cells were used to measure the response of ATF6 to ER stress (Fig. 1A) . Full-length ATF6 at 110 kDa represents the ER-localized protein, and the band at 65 kDa represents ATF6 that has trafficked to the Golgi and been cleaved. Cells were treated with the ER stress inducers dithiothreitol (DTT), tunicamycin (Tm), or thapsigargin (Tg) for varying times. DTT breaks disulfide bonds to unfold proteins, Tm blocks Nglycosylation of nascent polypeptides, and Tg inhibits ER calcium pumps. As a control, cells were treated with hydrogen peroxide (H 2 O 2 ), an oxidative stress agent. DTT induced a rapid shift in ATF6 to the processed form, causing cleavage of greater than half of cellular ATF6 within 30 min. Tm and Tg were both slower-acting, requiring 2-4 h for maximum effect. H 2 O 2 did not cause ATF6 cleavage (Fig. 1 A) . The localization of ATF6 was examined by immunofluorescence. ATF6 in unstressed or H 2 O 2 -treated cells was diffuse in the ER. During stress, ATF6 partially localized with a Golgi protein, Gos28, and displayed a more prominent nuclear localization, consistent with its trafficking (Fig. S1) .
To assess the mechanisms of ATF6 transport, we used an in vitro assay that recapitulated ER stress-induced vesicle budding. CHO-ATF6 cells were permeabilized with digitonin to allow access to intracellular organelles. This technique has been shown to generate functional ER membranes that maintain protein topology and resist protease treatment (13, 14) . In vitro COPII vesicle budding from the ER was induced by addition of GTP, rat liver cytosol, ATP, and an ATP regeneration system. After incubation to allow vesicle formation, membranes were removed The authors declare no conflict of interest. 1 To whom correspondence should be addressed. E-mail: schekman@berkeley.edu.
by sedimentation at low speed, and budded vesicles were collected by sedimentation at high speed. The packaging of 3ϫ-FLAG-ATF6 was compared with a positive control protein, ERGIC-53, a lectin that cycles between the ER and ER-Golgi intermediate compartment, and a negative control, Ribophorin-I, part of the oligosaccharyl transferase complex and a resident ER protein.
As a second positive control, we examined the budding of Sec22b, a v-SNARE that transports constitutively between the ER and Golgi.
ATF6 budded poorly in the standard reaction (Fig. 1B , lanes 4 and 5). When DTT was added into the reaction, ATF6 was enriched in vesicles (lanes 6-8). DTT did not affect ERGIC-53 or Sec22b budding, and did not cause significant Ribophorin-I release. No other toxin caused ATF6 budding. The inability of Tm and Tg to package ATF6 may seem in conflict with data from the cleavage assay ( Fig. 1 A) . However, DTT can act on folded proteins directly by reducing disulfide bonds, whereas Tm and Tg may act only indirectly on proteins as they are synthesized, conditions that likely do not occur in the cell-free transport reaction. Other reports have also shown that DTT, but not Tg, can induce ATF6 transport in the absence of protein synthesis (15) .
ATF6 packaging in the presence of DTT was 2-to 5-fold higher than in untreated membranes. The overall efficiency of ATF6 packaging in the presence of DTT was Ϸ5-10%. The efficiency of ATF6 transport was lower in vitro than in vivo after 1 h treatment with DTT. The decreased efficiency may be accounted for by the inaccessibility of the majority of natively folded, disulfide-linked proteins to reducing agents (16) . DTT will likely generate higher levels of unfolded proteins in cells engaged in protein synthesis, conditions that are not reproduced in our cell-free reaction.
We next examined the budding of endogenous ATF6 to determine whether the cell-free reaction reproduced transport of physiological levels of ATF6 (Fig. 1C) . We found that endogenous ATF6 in CHO.K1 cells was packaged with similar efficiency in response to DTT as FLAG-tagged ATF6 in stably transfected cells, demonstrating that the effect is valid for ATF6 expressed at normal levels.
In Vitro Packaging of ATF6 Requires Luminal Reducing Activity and COPII Proteins. We probed the requirement for a reducing agent using permeabilized cells treated with two membranepermeable reducing agents, DTT and ␤-mercaptoethanol (BME), and a membrane-impermeable reducing agent, Tris(2-Carboxyethyl) phosphine hydrochloride (TCEP) ( Fig. 2A) (17) . Both DTT and BME stimulated packaging, whereas TCEP had a small stimulatory effect at lower concentration and an inhibitory effect at higher concentration. The reducing potential of TCEP is greater than that of DTT at neutral pH (18) ; therefore, the levels of all chemicals were comparable. These results show that reducing activity in the lumen of the ER is necessary for ATF6 packaging into vesicles. Selective inhibitors were used to assess the role of COPII in ATF6 budding. A nonhydrolyzable GTP analog, GTP␥S, and a dominant negative Sar1, Sar1 H79G , both blocked budding of ATF6 and ERGIC-53 (Fig. 2B) . GDP had no effect, and WT Sar1 enhanced budding. Brefeldin A, which prevents retrograde transport from Golgi to ER, had a moderately inhibitory effect on all cargo, and the proteasome inhibitor ALLN had no effect. We conclude that ATF6 packaging depends on COPII.
Budded vesicles convey ATF6 to the Golgi membrane in vivo. Fusion of vesicles at the Golgi exposes ATF6 to Site-1 and Site-2 protease processing. We examined whether this fusion event occurred in our in vitro assay. We found no processing of ATF6, suggesting that the full transport event was not sustained in this reaction (Fig. S2 ).
ATF6 Physically Interacts with COPII for Transport. We examined the physical interaction of ATF6 with COPII on ER membranes using a prebudding assay in which purified COPII proteins are recruited to membranes and COPII-bound ER proteins isolated. The Sec23/24 complex is hypothesized to bind to a GTPrestricted Sar1 mutant, Sar1 H79G , but not to a GDP-restricted Sar1, Sar1 T39N (Fig. 3A) . Cargo is captured by Sec23/24 on membranes.
In the experiment, GST-Sar1 and Sec23/24 were mixed with membranes and the bound proteins on sedimented membranes solubilized with detergent to permit isolation of cargo complexes by immobilized glutathione. Salt-washed, permeabilized cells were untreated or pretreated with 2 mM DTT for 15 min in culture to mobilize ATF6 to ER exit sites. Immunoblot results (Fig. 3B) showed that both forms of GST-Sar1 were recruited to membranes, with Sar1 T39N binding slightly better to membranes than Sar1 H7G (Fig. 4B, ' 'membrane bound'' lanes 3 and 4, and 7 and 8). Sec23 bound to membranes incubated with Sar1 H79G , but less well to membranes incubated with Sar1 T39N , consistent with the requirement for GTP (lanes 1 and 2, and 5 and 6). ERGIC-53 served as a control protein for specific cargo binding, and Ribophorin-I served as a control for nonspecific binding. ERGIC-53 was recruited to Sar1 H79G /Sec23/24, whereas 5 and 6, and 11 and 12) . ATF6 was recruited in the Sar1 H79G /Sec23/24 condition after DTT treatment (lane 12). In four assays, DTT-stimulated binding of ATF6 to COPII was detected at 3-fold above untreated samples (Fig.  3C) . The efficiency of ATF6 binding was low compared with ERGIC-53 (0.5% ATF6; 2.5% ERGIC-53), a difference comparable with that seen in the budding assay. These results demonstrate that ATF6 forms physical association with COPII proteins under conditions of ER stress.
Ribophorin-I was not (lanes
We wished to assess the role of COPII as the sole cytosolic requirement for ATF6 packaging in our cell-free reaction. Cells were washed with 1 M KoAc to remove peripheral proteins, and purified COPII was added in a titration experiment. ATF6 and other cargo proteins were packaged in a COPII-concentration dependent manner (Fig. 3C) . ATF6, although less efficiently packaged than other cargo, was most stimulated by increasing amounts of COPII. These data demonstrate that ATF6 packaging requires no cytosolic components other than COPII.
ATP and DTT Synergistically Induce BiP Dissociation from ATF6 in Vitro.
ATF6 dissociation from BiP is necessary for transport (12) . To test whether stress reproduces this effect in vitro, permeabilized cells were treated with combinations of ATP and DTT, followed by FLAG-ATF6 immunoprecipitation and immunoblot of BiP (Fig. 4A ). Treatment with ATP or DTT alone caused approximately a 30% reduction in the ratio of BiP:ATF6 signal relative to untreated cells (Fig. 4B) . Although BiP has been found to stably associate with ATF6 (8), the high levels of ATP in the assay may allow some release of BiP. The combination of ATP and DTT reduced the association to Ͻ50%, and ATP␥S, a nonhydrolyzable analog of ATP, reduced the complex to Ͻ30% of the untreated control. These data demonstrate that DTT and ATP act together to release BiP from ATF6. This dissociation may trigger access of ATF6 to COPII.
BiP is normally retained in the ER. We examined the effect of DTT on the retention or transport of BiP (Fig. 4C) . BiP was found only at low levels in vesicles, and its packaging was not induced by DTT. Thus, it appears that ATF6 is packaged in the absence of BiP.
ATF6 Is Primed to Transport After in Vivo Treatment. We took advantage of the ability of DTT to mobilize ATF6 rapidly in vivo to assess whether DTT was required in the in vitro assay. CHO-ATF6 cells were pretreated in culture for 15 or 60 min with 2 mM DTT. This short time period was designed to mobilize ATF6 for transport while maintaining it in the ER. Permeabilized cells were washed to remove DTT and incubated in the budding reaction in parallel with nonpretreated controls (Fig.  5A ). ATF6 packaging was enhanced after pretreatment even in the absence of added DTT. In contrast, cells that were not pretreated displayed the standard DTT sensitivity, with little constitutive activity. A similar effect was seen after 60 min treatment, although budding efficiency was reduced from 15 min. Thus, the COPII-ATF6 interaction in vitro does not require the presence of reducing agent if ATF6 is primed for transport.
Treatment of membranes with high salt removes peripherally attached complexes. We examined the effect of such a treatment on DTT-induced packaging of ATF6 in vitro. Cells were either untreated or pretreated for 15 min with DTT before harvest, and both sets of permeabilized cells were salt washed with 1 M KoAc for 15 min (Fig. 5B) . This treatment reduced the overall budding efficiency, but did not alter the effects of pretreatment seen in Fig. 5A . These results demonstrate that the ATF6 complex formed during ER stress is stable to high salt treatment that removes most peripheral proteins.
ATF6 Is Actively Retained in the ER via Its Luminal Domain.
It has been established that the luminal domain of ATF6 controls its localization independent of the cytoplasmic domain (12) . We examined the contribution of the ATF6 luminal domain in the context of a constitutively transported protein, the v-SNARE Sec22b. Both Sec22b and ATF6 are single-pass, type II membrane proteins. The Sec22b sorting signal for COPII binding has been mapped to a structural motif near the ER membrane (19) .
We conducted cleavage assays on ATF6 and on constructs in which the ATF6 cytoplasmic domain was replaced with that of Sec22b. A constitutive transport mutant, ATF6 1-500 (⌬431-475) (12) , was cleaved in the presence or absence of ER stress, whereas a transport-deficient mutant ATF6 1-670 (⌬468-500) (12) , missing the luminal transport signal, remained intact with or without DTT (Fig. 6A) . These same constructs were generated with the Sec22b cytoplasmic domain (Fig. 6B) and also examined by cleavage assay. Sec22b-ATF6 TM migrated at the predicted 22-kDa size (lanes 9 and 10). The chimeric protein containing the full ATF6 luminal domain generated a cleaved species predominantly in the presence of DTT (lanes 3 and 4) . The luminal domain mutants (lanes 5-8) displayed the same phenotype as seen for ATF6 mutants (Fig. 6C) .
We used the COPII budding reaction to examine Sec22b-ATF6 TM and Sec22b-ATF6 transport activity. The transmembrane-only construct budded in the absence or presence of DTT, analogous to wild-type Sec22b. Sec22b-ATF6 transport showed high constitutive transport, likely because the Sec22b domain conferred some degree of transport. Still, it was stimulated 2.4-fold by DTT, showing that it was restrained in the absence of stress. Thus, in cells and in the cell-free budding reaction, the ATF6 retention signal overrode at least in part the constitutive Sec22b sorting signal.
Discussion
We report a cell-free vesicle budding reaction that recapitulates the ER-stress induced transport of the transcription factor ATF6. The addition of a reducing agent, DTT, mobilized ATF6 into COPII vesicles from the ER in the absence of protein synthesis. No other cytosolic adaptor proteins are required to package ATF6 into COPII vesicles. ATF6 dissociates from the luminal chaperon BiP (GRP78) in response to exogenous reducing agent in cells and in our cell-free reaction. The trigger for BiP dissociation may be proteins unfolded in response to reducing agent or a specific ϪSH reactive sensor protein, either of which may expose BiP to ATP binding and release from ATF6. By analogy, antibody light chain binding to heavy chain causes ATP release of BiP from heavy chain (20) .
We observed a basal level of constitutive transport of ATF6 in the absence of DTT, whereas the control protein Ribophorin-I was entirely excluded. ATF6 may have low levels of basal transport that serve to maintain cellular homeostasis. Reports have shown a role for ATF6 in development (21) and in the survival of dormant tumor cells (22) .
The experiments with Sec22-ATF6 fusion proteins show that ATF6 does not transport constitutively in the context of a strong COPII sorting signal (19) . ATF6 is present in a complex that displays slow diffusional mobility in the ER, possibly suggesting a higher-order complex (8) . ATF6 may interact with additional proteins besides BiP that restrain it from transport. Alternatively, the slow diffusion of ATF6 in the ER under unstressed conditions may limit its accessibility to COPII at ER exit sites.
These data suggest that BiP release from ATF6, triggered by unfolded proteins or a stress-sensor protein, is followed by recognition of ATF6 or a partner protein by COPII. Past experiments showed that ATF6 still transported when its cytoplasmic domain was replaced with the cytoplasmic domain of an ER-resident protein (11) , suggesting that transport involves a protein that mediates association between the luminal domain of ATF6 and the cytoplasmic COPII proteins. There are many examples of such receptors required to convey a membrane cargo protein into COPII vesicles (23) . Some receptors accompany membrane cargo proteins into the vesicle, whereas others are retained in the ER (24) . In the case of regulated transport, the best understood example is sterol control of SREBP, which depends on COPII binding to the cargo receptor SCAP (25) . A proteomic analysis of COPII vesicles formed under conditions permissive for ATF6 packaging may facilitate the identification of its sorting receptor.
Methods
Plasmids and Cell Lines. The WT, ⌬431-475, and ⌬468-500 human ATF6␣ cDNA with a 3ϫ N-terminal FLAG tag were gifts of R. Prywes (Columbia University, New York, NY) and are described elsewhere (12) . The original Sec22b cDNA was a gift of J. Hay (University of Montana, Missoula, MT). Chimeric Sec22-ATF6 proteins were made by amplifying Sec22b to include a 5Ј FLAG tag and exclude the 3Ј transmembrane region. PCR fragments were cloned into the pIRES2.neo (Clontech) backbone at StuI and ClaI sites. Transmembrane and luminal regions of ATF6 were PCR amplified to include a 5Ј ClaI site and a 3Ј XbaI site, and were cloned into the Sec22b.pIRES2 vector. All plasmids were sequenced before use.
Transfections were with Lipofectamine 2000 (Invitrogen) according to manufacturer's protocols. Transient transfections were conducted for 18 -24 h. For stable transfections in HeLa and CHO cells, plasmids were subcloned into the pIRES.hyg3 vector. Cells were kept in a 37°C incubator at 5% CO2.
Antibodies. Commercial antibodies were monoclonal ␣-FLAG M2 (Sigma), monoclonal ␣-Actin C4 (ICN Biomedicals), and rabbit polyclonal ␣-ATF6 and rabbit polyclonal ␣-Grp78 (Santa Cruz). Anti-Gos28 polyclonal antibody is described elsewhere (26) . Anti-ERGIC-53 antiserum was raised against an Escherichia coli purified GST fusion of amino acids 49 -484 in the rat protein. ␣-Ribophorin I was raised against C-terminal peptides corresponding to human protein (residues 588 -605) and mouse protein (residues 576 -605). The ␣-Sec22b was raised against a peptide corresponding to human residues 91-116. The ␣-Sar1 was raised against full-length, thrombin cleaved GSTfusion protein purified from E. coli.
Cleavage Assay. CHO-ATF6 cells or transfected HeLa cells were grown in 24-well plates to 90% confluency. Media was changed, and 1 h later cells were treated with toxins for indicated times. For harvesting, wells were washed 1ϫ with PBS, followed by addition of heated SDS sample buffer In Vitro Budding Assay. The in vitro vesicle budding assay was performed as described (27) . For description, see SI Methods.
Prebudding Assay. Prebudding complex pulldowns were performed as described previously (25) using permeabilized, salt-washed CHO-ATF6 cells. For description, see SI Methods.
BiP Dissociation and Immunoprecipitation. Permeabilized cells were incubated for 30 min at 22°C in the presence of 1 mM ATP or ATP␥S, or 5 mM DTT. Cells were washed three times and lysed for 1 h in 50 mM Tris, pH 8.0, 150 mM NaCl, 10% glycerol, 2 mM EDTA, and protease inhibitors. Lysates were pelleted at 14,000 ϫ g for 20 min, and supernatants cleared for 1 h with IgG Sepharose. ATF6:BiP complexes were isolated by incubation with 1 g ␣-FLAG M2 antibody conjugated to protein A Sepharose. Control reactions used 1 g monoclonal ␣-GFP (Roche).
Immunoblotting and Protein Quantification. Immunoblotting was carried out according to standard procedures, using either ECL plus enhanced chemiluminescence (Amersham) or an Odyssey infrared imaging system (Li-Cor Biosciences) with Alexa Fluor 680 ␣-rabbit (Invitrogen) or IR-dye 800 ␣-mouse (Molecular Probes) secondary antibodies.
Quantification of protein signal was performed on scanned membranes using Odyssey software or ImageJ. Budding efficiency was calculated by comparing the amount in each vesicle lane with the amount in the starting membrane lane. Prebudding efficiency was calculated by subtracting the background signal in the bound Sar1-GDP lane from the bound Sar1-GTP lane, and dividing by the amount present in a comparable aliquot of starting lysate. Lysates were loaded at 1% of total, and bound fractions loaded at 30% of total.
Immunofluorescence Microscopy and Protein Purification. For descriptions, see SI Methods.
